Ricerfarma S.r.l   Report issue

For profit Phase 3 Phase 4
Founded: Milan Italy (1996)
Status: No NME R&D (1996)

Organization Overview

First Clinical Trial
2013
NCT02931357
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (1)

guar gum (1 trial)

Drugs in Phase 3 Trials (3)

cetylpyridinium chloride (1 trial)

hyaluronic acid (1 trial)

lidocaine (xylocaine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Peri-Implantitis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4